Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
News|Articles|July 1, 2026
FDA News Recap: Novel Drug Approvals in First Half of 2026
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.
Advertisement
Advertisement
The first half of 2026 brought a wave of innovation across the medical community, with 22 novel drug approvals signaling major strides in disease treatment and management across a wide range of specialties.
Related to this article
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.
Advertisement
Advertisement